Autacoid pharmacology: histamine, serotonin, bradykinin, ergot alkaloids, eicosanoids & NSAIDs

Autacoids (derived from the Greek autos [self] and acos [remedy, relief, or drug]) are a heterogeneous family of biologically active endogenous substances synthesized, stored, and released locally in response to tissue injury, chemical irritation, or immunological stimuli. Functioning as “local hormones” or autocrine/paracrine signaling mediators, their physiological and pathological actions are predominantly restricted to the microenvironment immediately adjacent to their site of release.

Histamine (2-[4-imidazolyl]ethylamine) is an endogenous basic amine occurring ubiquitously across animal and plant tissues. In humans, high concentrations reside within epithelial boundary tissues directly interfacing with the external environment: the skin epidermis and dermis, bronchial and pulmonary mucosa, and the gastrointestinal tract mucosa.

1. Biosynthesis of Histamine

Histamine is synthesized from the essential dietary amino acid L-histidine in a single enzymatic step. The reaction involves decarboxylation catalyzed by the cytosolic enzyme histidine decarboxylase (HDC), which requires pyridoxal 5′-phosphate (Vitamin B₆) as an obligate cofactor.

2. Cellular Pools & Storage

• Mast Cell and Basophil Pool (Slow Turnover Pool): Histamine is sequestered inside dense, electron-rich secretory granules of tissue mast cells and circulating basophils. It is ionically bound in an electrostatically inactive complex with acidic, polyanionic proteoglycans (heparin sulfate in mast cells; chondroitin sulfate in basophils) and neutral proteases. Mast cells concentrate densely at sites prone to mechanical trauma or microbial entry: the nose, mouth, feet, internal mucosal surfaces, and along blood vessel bifurcations.
• Non-Mast Cell Pool (Fast Turnover Pool): Histamine is synthesized continuously and released immediately without long-term granular storage:
  • Enterochromaffin-Like (ECL) Cells: Located in the gastric fundic oxyntic mucosa; release histamine upon gastrin and vagal muscarinic (M₁/M₃) stimulation to activate adjacent acid-secreting parietal cells via H₂ receptors.
  • Central Histaminergic Neurons: Cell bodies localized strictly in the tuberomammillary nucleus of the posterior hypothalamus. They project diffusely across the neuroaxis, regulating wakefulness, circadian arousal, appetite suppression, neuroendocrine release, and body temperature.

3. Mechanisms of Histamine Release

4. Metabolism & Inactivation of Histamine

Circulating and local histamine is rapidly metabolized by two distinct enzymatic pathways:

• 1. Histamine N-Methyltransferase (HNMT) Pathway (Primary Pathway, ~70%): Prevalent in parenchymal tissues (especially brain, liver, and kidneys), but completely absent in circulating blood. HNMT transfers a methyl group from S-adenosylmethionine (SAM) to the imidazole nitrogen, yielding 1-methylhistamine (tele-methylhistamine). Monoamine oxidase B (MAO-B) and aldehyde dehydrogenase subsequently oxidize it into 1-methylimidazole-4-acetic acid, which is excreted in the urine.
• 2. Diamine Oxidase (DAO / Histaminase) Pathway (Secondary Pathway, ~30%): Present in intestinal mucosa, liver, kidney, and circulating plasma. Catalyzes oxidative deamination of the primary aliphatic amine group, forming imidazole-4-acetic acid and its riboside conjugate. DAO plays an essential defense role in catabolizing high concentrations of histamine ingested in fermented or spoiled foods (preventing dietary histamine toxicity).

Histamine acts through four distinct, non-selective G-protein coupled receptor (GPCR) subtypes designated H₁, H₂, H₃, and H₄. Structurally, H₁ receptors share close phylogenetic homology with muscarinic acetylcholine receptors, whereas H₂ receptors share sequence alignment with serotonergic 5-HT₁ receptors.

The pathophysiological actions of histamine can be pharmacologically attenuated via three distinct clinical mechanisms: physiological antagonism, mast cell release inhibition, and receptor antagonism (inverse agonism).

1. Physiological Antagonists

Adrenaline (Epinephrine): Operates as the ultimate life-saving physiological antagonist. It does not interact with histamine receptors; instead, it binds to β₂-adrenoceptors on bronchial smooth muscle (reversing bronchospasm), α₁-adrenoceptors on vascular smooth muscle (reversing vasodilation and mucosal edema, elevating blood pressure), and β₂ receptors on mast cells (suppressing further mediator release). It is the mandatory, immediate first-line drug of choice for systemic anaphylaxis (0.3 to 0.5 mg IM in adults).

2. Release Inhibitors (Mast Cell Stabilizers)

Cromolyn Sodium & Nedocromil: Inhibit chloride channels in the mast cell membrane, blocking the antigen-stimulated transmembrane influx of Ca²⁺ required for exocytic degranulation. They prevent the release of histamine, leukotrienes, and secondary autacoids, while suppressing leukocyte chemotaxis. Critical Caveat: They possess zero direct bronchodilator or antihistaminic action; they are exclusively prophylactic agents and are ineffective if administered during an acute allergic or asthmatic attack.

3. H₁-Receptor Antagonists (Antihistamines)

All modern H₁ blockers act molecularly as inverse agonists that bind and stabilize the inactive conformation of the H₁ receptor, downregulating constitutive basal signaling. They are categorized into three generations:

4. H₂-Receptor Antagonists

Competitive, reversible antagonists at parietal cell H₂ receptors: Cimetidine, Ranitidine, Famotidine, and Nizatidine.

• Relative Potencies: Ranitidine is 5 times more potent than cimetidine; Famotidine is 5 times more potent than ranitidine (25-fold more potent than cimetidine).
• Therapeutic Indications: Duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), and prevention of stress-related mucosal bleeding.
• Cimetidine Adverse Effects & Toxicity:
  • Antiandrogenic Effects: Binds androgen receptors and inhibits dihydrotestosterone, while stimulating prolactin secretion; chronic therapy produces gynecomastia, galactorrhea, and reduced sperm count/impotence in men.
  • CYP450 Enzyme Inhibition: Potent inhibitor of CYP1A2, CYP2C9, CYP2D6, and CYP3A4, dangerously elevating serum levels of co-administered narrow-therapeutic-index drugs (warfarin, theophylline, phenytoin, lidocaine). Ranitidine exhibits negligible CYP inhibition; famotidine exhibits zero CYP inhibition.

Serotonin (5-Hydroxytryptamine, 5-HT) is an endogenous indoleethylamine autacoid and neurotransmitter synthesized widely across animal tissues, plants, fruits, and venoms.

1. Anatomical Distribution in Humans

• Gastrointestinal Enterochromaffin (EC) Cells (~90% of Total Body Pool): Synthesized and stored within mucosal enterochromaffin cells of the stomach and small intestine; regulates peristaltic motor reflexes and secretory activity.
• Circulating Blood Platelets (~8% of Total Body Pool): Platelets do not synthesize serotonin (they lack tryptophan hydroxylase). They take up free 5-HT from intestinal mesenteric circulation via high-affinity Serotonin Transporters (SERT) and store it in dense core granules; released during platelet activation to promote local vasoconstriction and hemostatic plug formation.
• Central Nervous System Neurons (~1–2% of Total Body Pool): Synthesized and stored in the raphe nuclei of the midbrain, pons, and medulla; modulates mood, sleep, appetite, vomiting, nociception, and thermoregulation.

2. Biosynthesis & Degradation

Serotonin is synthesized from essential dietary L-tryptophan via two sequential enzymatic steps:

1. Hydroxylation (Rate-Limiting Step): Tryptophan is hydroxylated at the 5-position by the rate-limiting enzyme tryptophan hydroxylase (TPH) to yield 5-hydroxytryptophan (5-HTP). TPH is confined to 5-HT-producing cells and is absent in platelets.
2. Decarboxylation: 5-HTP is rapidly converted to 5-hydroxytryptamine (5-HT) by ubiquitous aromatic L-amino acid decarboxylase (dopa decarboxylase).

Following release, 5-HT is taken back up via SERT and degraded primarily by monoamine oxidase A (MAO-A) and aldehyde dehydrogenase into 5-hydroxyindoleacetic acid (5-HIAA), which is excreted in urine. A minor alternative pathway forms 5-hydroxytryptophol via alcohol dehydrogenase.

3. Storage & Vesicular Transport

Cytosolic 5-HT is transported into dense intracellular storage vesicles by the Vesicular Monoamine Transporter (VMAT-2). The plant alkaloid reserpine irreversibly inhibits VMAT-2, depleting vesicular serotonin stores across both platelets and central serotonergic terminals (mimicking its depletion of norepinephrine in adrenergic terminals).

Serotonin acts upon seven distinct receptor families (5-HT₁ through 5-HT₇) comprising at least 14 molecular subtypes. All are G-protein coupled receptors, with one critical exception: the 5-HT₃ receptor is a ligand-gated ion channel.

1. Carcinoid Syndrome

Carcinoid syndrome is a clinical disorder associated with neuroendocrine tumors arising from enterochromaffin (Kulchitsky) cells of the gastrointestinal tract (most commonly the terminal ileum or appendix). Because primitive gut hormones drain directly into the portal circulation and are metabolized by hepatic monoamine oxidases, clinical carcinoid syndrome typically emerges only after the tumor has metastasized to the liver (allowing mediators direct access to hepatic veins and systemic circulation) or originates in primary extra-portal sites (e.g., bronchial carcinoids).

• Secreted Mediators: 5-Hydroxytryptamine is the predominant mediator, accompanied by tachykinins (Substance P, Neurokinin A), histamine, prostaglandins, kallikrein, and motilin.
• Clinical Manifestations: Paroxysmal cutaneous flushing of the face and upper chest; explosive, watery diarrhea and abdominal cramping; asthmatic wheezing and dyspnea; hypotension; and right-sided cardiac valvular lesions (fibrotic thickening of the tricuspid and pulmonic valves leading to right heart failure). Left heart valves are protected because serotonin is catabolized by pulmonary endothelial MAO-A.
• Medical Management:
  • Octreotide: A synthetic somatostatin analog that binds somatostatin (sstr2) receptors, suppressing tumor secretion of 5-HT and peptides (the definitive drug of choice).
  • Cyproheptadine: A combined 5-HT₂ and H₁ receptor antagonist that relieves intestinal hypermotility and diarrhea.

2. Pathophysiology of Migraine Headache

Migraine is a neurovascular disorder characterized by severe, throbbing, unilateral headache attacks accompanied by photophobia, phonophobia, nausea, and vomiting. Approximately one-third of patients experience an antecedent aura phase (scintillating scotomas, visual field loss, paresthesias) driven by a self-propagating wave of cortical neuronal and glial depolarization termed cortical spreading depression (CSD).

• The Trigeminovascular Cascade: CSD triggers opening of neuronal pannexin-1 megachannels, activating caspase-1 and liberating pro-inflammatory cytokines that stimulate nuclear factor kappa-B (NF-κB). This inflammatory cascade excites perivascular sensory nerve fibers of the ophthalmic division of the trigeminal nerve (CN V₁) encircling pial and dural vessels.
• Neurogenic Inflammation & Neuropeptides: Activated trigeminal afferents release potent vasoactive neuropeptides: Calcitonin Gene-Related Peptide (CGRP), Substance P, and Neurokinin A. CGRP induces marked dural arteriolar vasodilation, while Substance P promotes microvascular leakage and mast cell degranulation. The resulting mechanical distension of dural vessels stimulates perivascular nociceptors, transmitting throbbing pain signals into the trigeminal nucleus caudalis and sensory cortex.
• Role of 5-HT in Migraine: Plasma 5-HT falls precipitously during the onset of a migraine attack. A baseline deficit in central serotonergic pain-inhibition systems allows uninhibited trigeminal nociceptive firing.

1. 5-HT_1D/1B Receptor Agonists (The Triptans)

The triptans (Sumatriptan [prototype], Naratriptan, Rizatriptan, Zolmitriptan, Eletriptan) are the first-line pharmacotherapy for acute, moderate-to-severe migraine attacks and cluster headaches.

• Dual Mechanism of Action:
  1. Presynaptic 5-HT_1D Agonism: Binds G_i-coupled 5-HT_1D autoreceptors on perivascular trigeminal sensory nerve terminals, blocking the exocytosis of CGRP, Substance P, and pro-inflammatory neuropeptides, halting neurogenic inflammation.
  2. Postsynaptic 5-HT_1B Agonism: Directly stimulates 5-HT_1B receptors on vascular smooth muscle of distended intracranial and meningeal blood vessels, inducing selective vasoconstriction to prevent mechanical stretching of nociceptors.
• Adverse Effects: Paresthesias, warmth, dizziness, and “triptan chest tightness” (transient retrosternal tightness or throat constriction).
• Cardiovascular Contraindications: Strictly contraindicated in patients with documented ischemic coronary artery disease, angina pectoris, prior myocardial infarction, uncontrolled hypertension, peripheral vascular disease, or basilar/hemiplegic migraine, as they can precipitate coronary vasospasm and acute myocardial ischemia.

2. 5-HT_1A Partial Agonists

Buspirone: A partial agonist at somatodendritic 5-HT_1A autoreceptors in the dorsal raphe and postsynaptic receptors in the limbic cortex. Used as a non-benzodiazepine anxiolytic for generalized anxiety disorder (GAD). Does not interact with GABA receptors; lacks sedative, anticonvulsant, and muscle-relaxant actions; and carries zero potential for tolerance, dependence, or physical abuse.

3. 5-HT₂ Receptor Antagonists

• Cyproheptadine: Blocks 5-HT_2A and histamine H₁ receptors, with significant anticholinergic actions. Indicated for controlling diarrhea and flushing in carcinoid syndrome, cold-induced urticaria, and as an appetite stimulant. It is also the specific drug of choice for managing mild-to-moderate Serotonin Syndrome.
• Ketanserin: Potent competitive 5-HT_2A antagonist with concurrent α₁-adrenoceptor blocking actions; inhibits platelet aggregation and lowers blood pressure via α₁ vasodilation.
• Methysergide & Pizotifen: Prophylactic migraine agents. Methysergide was withdrawn due to its dangerous propensity to cause retroperitoneal, pleural, and cardiac valvular fibrotic reactions leading to obstructive uropathy and renal failure.
• Clozapine & Atypical Antipsychotics: Antagonize 5-HT_2A/2C and dopamine D₂ receptors; treats refractory schizophrenia with reduced extrapyramidal motor side effects.

4. 5-HT₃ Receptor Antagonists

Ondansetron, Granisetron, Dolasetron, Tropisetron, Palonosetron: Competitive antagonists at ligand-gated 5-HT₃ receptors located in the chemoreceptor trigger zone (area postrema) and peripheral vagal afferents in the upper gastrointestinal tract. They are first-line antiemetics for preventing chemotherapy-induced nausea and vomiting (CINV), post-radiation emesis, and postoperative nausea and vomiting (PONV).

5. 5-HT₄ Receptor Agonists (Prokinetics)

Tegaserod & Cisapride: Stimulate 5-HT₄ receptors on prejunctional cholinergic motor neurons of the myenteric plexus, promoting acetylcholine release to enhance coordinated gastrointestinal peristalsis. Indicated historically for irritable bowel syndrome with constipation (IBS-C). Cisapride was restricted due to inhibition of cardiac HERG K⁺ channels, causing QT prolongation and fatal torsades de pointes.

6. Selective Serotonin Reuptake Inhibitors (SSRIs)

Fluoxetine, Sertraline, Paroxetine, Fluvoxamine, Citalopram, Escitalopram: Selectively inhibit the serotonin transporter (SERT), preventing 5-HT reuptake and elevating synaptic serotonin concentrations throughout the CNS. First-line pharmacotherapy for major depressive disorder, generalized anxiety, panic disorder, obsessive-compulsive disorder (OCD), and bulimia nervosa.

Bradykinin is a potent vasoactive nonapeptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) generated within circulating plasma and inflamed tissues. It serves as a cardinal chemical mediator of acute inflammation, pain sensation, and hemodynamic autoregulation.

1. Synthesis & Degradation

• Enzymatic Cleavage: Bradykinin is derived from high-molecular-weight kininogen (HMWK) in plasma and low-molecular-weight kininogen (LMWK) in tissue lymph. Activated coagulation Factor XIIa (Hageman factor) converts plasma prekallikrein into kallikrein, a serine protease that cleaves kininogens into bradykinin (in plasma) and kallidin (lysyl-bradykinin, in tissues).
• Rapid Inactivation: Bradykinin has an elimination half-life of <30 seconds. Over 90% is degraded on first pass through the pulmonary vascular bed by kininase II, an enzyme biochemically identical to Angiotensin-Converting Enzyme (ACE). Neutral endopeptidase (neprilysin) also catabolizes kinins.

2. Receptor Subtypes & Pharmacodynamics

• B₁ Receptor: Minimally expressed under normal physiological conditions; rapidly upregulated (induced) by pro-inflammatory cytokines (IL-1β, TNF-α) and tissue injury. Mediates chronic inflammatory pain and sustained hyperalgesia.
• B₂ Receptor: A constitutively active GPCR coupled to G_q/11 (activating PLC → IP₃, DAG → intracellular Ca²⁺ and protein kinase C). Mediates virtually all acute physiological and inflammatory actions of bradykinin:
  • Vasodilation & Hypotension: Stimulates endothelial B₂ receptors to release nitric oxide (NO) and prostacyclin (PGI₂), causing potent arteriolar dilation. In the kidneys, it promotes renal medullary vasodilation and natriuresis by inhibiting tubular sodium reabsorption.
  • Increased Microvascular Permeability: Induces contraction of postcapillary venular endothelial cells, causing massive plasma extravasation, blister formation, and angioedema.
  • Nociception (Algesia): Directly excites nociceptive primary sensory afferents and provokes the release of substance P and CGRP, generating severe, sharp pain amplified synergistically by prostaglandins.
  • Bronchoconstriction: Powerful spasmogen of airway smooth muscle; inhaled bradykinin induces severe bronchospasm in asthmatic patients.

3. Clinical Therapeutics & Pathology

• Aprotinin (Trasylol): A natural broad-spectrum serine protease inhibitor that blocks plasma and tissue kallikreins, plasmin, and trypsin. Used clinically to reduce perioperative blood loss and transfusion requirements during coronary artery bypass graft (CABG) surgery.
• Icatibant: A synthetic decapeptide that acts as a competitive, selective B₂ receptor antagonist. Indicated for the subcutaneous treatment of acute, life-threatening attacks of Hereditary Angioedema (HAE) caused by C1-esterase inhibitor deficiency.
• ACE-Inhibitor-Induced Cough and Angioedema: ACE inhibitors (captopril, enalapril) block kininase II, preventing bradykinin degradation. Bradykinin and substance P accumulate in the upper respiratory tract, triggering a persistent, intractable dry cough in up to 15% of patients, and potentially fatal angioedema of the lips, tongue, and larynx.

Ergot alkaloids are complex, nitrogenous polycyclic compounds produced by Claviceps purpurea, a parasitic fungus that infests rye and other cereal grains. Historically, ingestion of contaminated grain caused epidemics of “St. Anthony’s Fire” (ergotism), characterized by intense burning pain, hallucinations, severe peripheral vasoconstriction, and ischemic gangrene of the extremities.

1. Chemical Classification

• Amine Alkaloids: Simple lysergic acid amide derivatives: Ergonovine (ergometrine), Methylergonovine, Methysergide, and the psychedelic hallucinogen Lysergic acid diethylamide (LSD).
• Peptide (Amino Acid) Alkaloids: Complex cyclic tripeptide moieties attached to lysergic acid: Ergotamine, α-Ergocryptine, and Bromocriptine.

2. Receptor Pharmacology & Mechanism

Ergot alkaloids are notorious for non-selective, promiscuous receptor interactions, acting as agonists, partial agonists, or antagonists across three major biogenic amine GPCR families:

• α-Adrenoceptors: Agonist and partial agonist activity drives potent, long-lasting peripheral and cerebral arterial vasoconstriction; antagonist activity at higher concentrations.
• Serotonin (5-HT) Receptors: High affinity for 5-HT_1A, 5-HT_1D, and 5-HT₂ receptors; mediates acute antimigraine efficacy and smooth muscle spasm.
• Dopamine Receptors: Selective agonists or partial agonists at central dopamine D₂ receptors (particularly bromocriptine and cabergoline).

3. Organ System Effects & Clinical Applications

4. Adverse Effects & Contraindications

• Vasospasm & Gangrene: Ergotamine induces prolonged, cumulative arterial spasm. Overdose or co-administration with strong CYP3A4 inhibitors (macrolides, protease inhibitors) causes severe ischemic pain, absent pulses, and dry gangrene of fingers and toes.
• Gastrointestinal Disturbance: Nausea, vomiting, and abdominal pain are common due to direct activation of the medullary chemoreceptor trigger zone (CTZ).
• Contraindications: Absolutely contraindicated in pregnancy (potent abortifacient action), uncontrolled hypertension, peripheral vascular disease, coronary artery disease, and severe hepatic/renal impairment.

The eicosanoids (Greek eikosi, twenty) are oxygenated, polyunsaturated 20-carbon fatty acid autacoids synthesized de novo from cell membrane phospholipids in response to mechanical trauma, cytokines, or chemical stimuli. They are not stored preformed inside cellular granules.

1. Liberation of Arachidonic Acid

The universal obligate precursor is arachidonic acid (5,8,11,14-eicosatetraenoic acid), an essential ω-6 fatty acid esterified at the sn-2 position of membrane phospholipids. Cellular activation triggers the calcium-dependent enzyme phospholipase A₂ (PLA₂) to cleave and release free arachidonic acid into the cytoplasm. Glucocorticoids inhibit this step by inducing the synthesis of inhibitory proteins termed annexins (lipocortins).

2. The Cyclooxygenase (COX) Pathway

Free arachidonic acid is converted by the bifunctional enzyme cyclooxygenase (endoperoxide synthase) via a two-step reaction: (1) cyclooxygenase adds molecular oxygen to yield unstable PGG₂, and (2) peroxidase reduces PGG₂ into unstable PGH₂. Tissue-specific synthases convert PGH₂ into active prostanoids:

• Prostacyclin (PGI₂): Synthesized primarily by vascular endothelial cells via prostacyclin synthase. Acts on IP receptors (G_s → ↑ cAMP) to induce potent vasodilation, inhibit platelet aggregation, maintain patency of the ductus arteriosus, and promote gastric mucosal cytoprotection.
• Thromboxane A₂ (TXA₂): Synthesized exclusively in platelets via thromboxane synthase. Acts on TP receptors (G_q → ↑ IP₃/Ca²⁺) to induce platelet aggregation, intense vasoconstriction, and bronchoconstriction. PGI₂ and TXA₂ form a critical physiological antagonistic balance regulating vascular hemostasis.
• Prostaglandin E₂ (PGE₂): Ubiquitously synthesized; acts on four distinct G-protein coupled receptors:
  • EP₁ (G_q): Smooth muscle contraction, hyperalgesia.
  • EP₂ & EP₄ (G_s → ↑ cAMP): Vasodilation, bronchodilation, maintenance of renal blood flow, cervical ripening.
  • EP₃ (G_i → ↓ cAMP): Inhibits gastric acid secretion, stimulates protective mucin and bicarbonate secretion, contracts uterine smooth muscle, and elevates anterior hypothalamic thermoregulatory set-point (inducing fever in response to IL-1 and pyrogens).
• Prostaglandin F_2α (PGF_2α): Synthesized in the myometrium, lungs, and eye; acts on FP receptors (G_q) to contract the pregnant uterus, contract bronchioles, and increase uveoscleral outflow of aqueous humor.
• Prostaglandin D₂ (PGD₂): Produced by mast cells and brain; acts on DP receptors to induce bronchoconstriction, vasodilation, and non-REM sleep.

3. The Lipoxygenase (5-LOX) Pathway

In inflammatory leukocytes (neutrophils, eosinophils, basophils, macrophages), arachidonic acid is oxygenated by 5-lipoxygenase (5-LOX) in the presence of 5-lipoxygenase activating protein (FLAP) to form 5-HPETE, which is converted to unstable leukotriene A₄ (LTA₄):

• Leukotriene B₄ (LTB₄): Produced via LTA₄ hydrolase; acts on BLT₁ receptors as an extraordinarily potent chemoattractant for neutrophils, stimulating leukocyte adhesion to endothelium, trans-endothelial migration, degranulation, and lysosomal enzyme release.
• Cysteinyl Leukotrienes (LTC₄, LTD₄, LTE₄): Formed by conjugating glutathione to LTA₄ (peptidoleukotrienes). Formerly designated “Slow-Reacting Substance of Anaphylaxis” (SRS-A). Act on CysLT₁ receptors as potent bronchoconstrictors (1000-fold more potent than histamine), promoting airway mucosal edema, plasma exudation, and hypersecretion in bronchial asthma.

Inflammation is a protective homeostatic vascular and cellular response to tissue injury caused by physical trauma, noxious chemicals, or invading microbiological pathogens. Its physiological objective is to isolate and destroy the inciting insult, clear necrotic debris, and initiate tissue repair. If over-vigorous or dysregulated, acute inflammation can transition into debilitating chronic inflammatory and autoimmune pathology.

1. Cardinal Signs of Acute Inflammation

1. Redness (Rubor): Local microvascular arteriolar vasodilation increasing regional blood flow (hyperemia); mediated by histamine, prostaglandins (PGI₂, PGE₂), and nitric oxide.
2. Heat (Calor): Increased local temperature due to sustained vascular hyperemia and elevated perfusion.
3. Pain (Dolor): Hyperalgesia resulting from direct nociceptor stimulation by bradykinin and 5-HT, markedly sensitized by PGE₂ and PGI₂.
4. Swelling (Tumor): Increased microvascular permeability causing postcapillary venular endothelial gap formation, allowing plasma protein leakage into the extravascular interstitial space (edema).
5. Loss of Function (Functio Laesa): Functional limitation produced by local mechanical swelling and reflex pain inhibition.

2. The Cyclooxygenase Isozymes

Cyclooxygenase exists in three distinct structural and functional isoforms:

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are among the most widely prescribed therapeutic agents worldwide. They share three primary clinical actions: analgesia (pain relief), antipyresis (fever reduction), and anti-inflammatory activity. They act fundamentally by inhibiting cyclooxygenase enzymes, preventing eicosanoid biosynthesis.

1. Chemical Classification of NSAIDs

• Salicylates: Acetylsalicylic acid (Aspirin), Sodium salicylate, Diflunisal, Sulfasalazine.
• Propionic Acid Derivatives: Ibuprofen, Naproxen, Ketoprofen, Flurbiprofen, Fenoprofen, Oxaprozin.
• Acetic Acid Derivatives:
  • Indole Acetic Acids: Indomethacin, Sulindac.
  • Phenylacetic Acids: Diclofenac.
  • Pyrrolo-Pyrrole Derivatives: Ketorolac.
• Oxicam Derivatives: Piroxicam, Tenoxicam, Meloxicam.
• Fenamates (Anthranilic Acids): Mefenamic acid, Meclofenamate.
• Pyrazolone Derivatives: Phenylbutazone, Oxyphenbutazone, Sulfinpyrazone, Metamizole.
• Sulfonanilide Derivatives: Nimesulide.
• Selective COX-2 Inhibitors (Coxibs): Celecoxib, Etoricoxib, Parecoxib.
• Para-Aminophenol Derivatives: Paracetamol (Acetaminophen).

2. General Pharmacokinetics of NSAIDs

• Absorption: Administered orally, parenterally, rectally, and topically. Most are weak organic acids (pKa 3.0 to 5.0). Completely absorbed from the stomach and upper small intestine; oral bioavailability is high (>80%) as they undergo minimal first-pass hepatic metabolism. Food may delay absorption rate, but does not decrease total bioavailability.
• Plasma Protein Binding: Extensively bound to plasma albumin (≥95% to 99%). Highly prone to competitive displacement interactions, displacing co-administered drugs like warfarin, sulfonylureas (glibenclamide), and methotrexate, potentially triggering toxicity.
• Tissue Distribution & Synovial Penetration: Distribute broadly into extracellular fluids and inflame joints. All NSAIDs penetrate readily into synovial fluid; drugs with short elimination half-lives (e.g., ibuprofen, diclofenac) persist in synovial compartments long after plasma concentrations decline, maintaining prolonged clinical joint efficacy.
• Metabolism & Excretion: Extensively metabolized in the liver via phase I cytochrome P450 oxidation (predominantly CYP2C9 and CYP3A4) followed by phase II glucuronide conjugation. Cleared predominantly by renal excretion. Many agents (e.g., indomethacin, sulindac, piroxicam) undergo significant enterohepatic recirculation, which correlates with severe lower gastrointestinal mucosal damage and ulceration.

1. Aspirin: The Irreversible Prototype

Aspirin (Acetylsalicylic Acid, ASA) is the historic prototype to which all NSAIDs are compared. Its molecular mechanism is unique among NSAIDs:

• Covalent Irreversible Inactivation: Aspirin covalently acetylates a specific serine residue (Serine-529 in COX-1; Serine-516 in COX-2) located near the catalytic active site. This sterically obstructs arachidonic acid from entering the cyclooxygenase channel, permanently abolishing enzymatic activity. All other traditional NSAIDs (ibuprofen, naproxen, indomethacin) are reversible competitive inhibitors.
• The Platelet Thromboxane Paradox: Blood platelets possess COX-1 to synthesize pro-aggregatory TXA₂. Because mature platelets lack nuclei, they cannot transcribe mRNA or synthesize new protein; inhibition of platelet COX-1 is permanent and lasts for the entire lifespan of the platelet (7 to 10 days). Conversely, vascular endothelial cells have nuclei and regenerate new COX-1/COX-2 within hours, restoring anti-aggregatory prostacyclin (PGI₂) synthesis. Therefore, low-dose aspirin (75 to 100 mg/day) produces selective, cardioprotective antiplatelet inhibition without suppressing endothelial PGI₂.
• Dose-Dependent Spectrum of Action:
  • Low Doses (75 to 150 mg/day): Selective irreversible antiplatelet aggregation; secondary prevention of myocardial infarction, ischemic stroke, and transient ischemic attacks (TIAs).
  • Moderate Doses (300 to 2400 mg/day): Analgesic and antipyretic actions.
  • High Anti-Inflammatory Doses (3.2 to 4.5 g/day): Effective anti-inflammatory activity for acute rheumatic fever and severe rheumatoid arthritis (frequently causes salicylism).
  • Uric Acid Biphasic Actions: Low-to-moderate doses (<2 to 3 g/day) compete with uric acid for active renal tubular secretion, inducing hyperuricemia (worsening gout); high doses (>5 g/day) inhibit renal tubular reabsorption of uric acid, producing uricosuria. Rule: Aspirin is avoided in gout.

2. Adverse Effects of Aspirin & Traditional NSAIDs

• Gastric Mucosal Ulceration & Ion Trapping: Prostaglandin deficiency removes mucosal cytoprotection. In addition, aspirin is a weak acid (pKa 3.5) that remains non-ionized and lipophilic within acidic gastric juice (pH 1.5 to 2.0). It diffuses across the gastric epithelial cell membrane into neutral cytoplasm (pH 7.1), where it immediately ionizes into charged salicylate and H⁺ ions. These charged ions cannot diffuse out, becoming “ion trapped” inside the mucosal cell, causing cell edema, necrosis, subepithelial hemorrhage, and peptic ulceration.
• Aspirin-Exacerbated Respiratory Disease (AERD / Samter’s Triad): A non-IgE pseudoallergic reaction occurring in up to 10–20% of asthmatics with nasal polyps and chronic rhinosinusitis. Blocking COX shunts arachidonic acid entirely down the 5-lipoxygenase pathway, generating a massive surge in cysteinyl leukotrienes (LTC₄, LTD₄) that triggers severe, life-threatening bronchospasm.
• Reye’s Syndrome: Administration of aspirin to children and adolescents during febrile viral illnesses (influenza A/B, varicella/chickenpox) is strongly linked to Reye’s syndrome: acute mitochondrial injury causing microvesicular hepatic steatosis, fulminant hepatic failure, hyperammonemia, and lethal cerebral edema. Aspirin is strictly contraindicated in pediatric patients with viral fever; paracetamol or ibuprofen must be used instead.
• Renal Toxicity: In high-risk states (congestive heart failure, cirrhosis, hypovolemia, pre-existing chronic kidney disease), renal perfusion relies on vasodilating prostaglandins (PGE₂, PGI₂) maintaining afferent arteriolar dilation. NSAIDs block these prostaglandins, precipitating acute renal vasoconstriction, acute kidney injury (AKI), sodium and water retention (blunting antihypertensives and diuretics), hyperkalemia, and chronic renal papillary necrosis.

3. Acute Salicylate Poisoning (Salicylism)

• Toxic Doses: Serious toxicity occurs above 150 mg/kg; lethal doses range from 15 to 30 grams in adults (lower in children).
• Clinical Progression: Early toxicity (salicylism) presents with tinnitus, high-frequency hearing loss, vertigo, nausea, vomiting, and diaphoresis. Salicylates directly stimulate the medullary respiratory center, causing hyperventilation (hyperpnea) and initial respiratory alkalosis. Subsequently, toxic concentrations uncouple mitochondrial oxidative phosphorylation, causing anaerobic glycolysis, accumulation of lactic acid and pyruvic acid, and hyperthermia. Combined with circulating salicylate ketoacids, this produces a severe, life-threatening mixed respiratory alkalosis and high anion-gap metabolic acidosis, central respiratory depression, coma, and cardiorespiratory arrest.
• Emergency Management:
  1. Gastric decontamination: Gastric lavage and repeated doses of activated charcoal.
  2. Aggressive intravenous fluid resuscitation to correct dehydration and hypokalemia.
  3. Urinary Alkalinization: Intravenous infusion of sodium bicarbonate (NaHCO₃) to titrate urine pH to 7.5–8.5. Alkalinization ionizes salicylic acid into polar salicylate inside renal tubular lumens, preventing reabsorption (“ion trapping”) and increasing renal excretion up to twenty-fold.
  4. Hemodialysis for severe poisoning (salicylate level >100 mg/dL, refractory acidosis, or renal failure).
  5. Intramuscular Vitamin K to correct hypoprothrombinemia.

4. Individual Non-Selective NSAIDs

• Ibuprofen: Phenylpropionic acid derivative with the best overall gastrointestinal safety profile among non-selective NSAIDs. Doses of 2400 mg/day equal 4 g of aspirin in anti-inflammatory efficacy; lower doses (<2400 mg/day) are analgesic/antipyretic. Available as topical creams, oral liquid gels, and IV infusions. Used intravenously to close patent ductus arteriosus (PDA) in premature infants with efficacy equal to indomethacin and less renal impairment. Drug Interaction: Reversibly blocks the platelet COX-1 binding site, antagonizing the irreversible antiplatelet action of aspirin if taken prior to aspirin.
• Indomethacin: Indole acetic acid derivative; exceptionally potent non-selective COX inhibitor that also directly inhibits neutrophil motility. First-line therapy for acute gouty arthritis, ankylosing spondylitis, and medical closure of patent ductus arteriosus. Characterized by high toxicity: severe frontal headaches (in 25–50% of patients), dizziness, confusion, depression, acute psychosis with hallucinations, pancreatitis, and renal papillary necrosis. Probenecid inhibits its renal and biliary clearance.
• Diclofenac: Phenylacetic acid derivative with high potency. Concentrates extensively in synovial fluid. Causes significant gastrointestinal ulceration; often co-formulated with misoprostol (Arthrotec) or omeprazole. Topical 3% gel is effective for actinic (solar) keratoses; 0.1% ophthalmic drops prevent postoperative ocular inflammation. Carries higher cardiovascular risk than naproxen.
• Ketorolac: Potent analgesic with weak anti-inflammatory action; administered parenterally (IM/IV) or orally for severe acute postoperative pain. Because of extreme nephrotoxicity and gastrointestinal ulceration risk, therapy is strictly limited to a maximum duration of 5 days.
• Naproxen: Propionic acid derivative with a long half-life (14 hours, permitting BID dosing). Exhibits the lowest cardiovascular risk profile among traditional NSAIDs; preferred in patients with high baseline cardiovascular disease.
• Piroxicam: Oxicam derivative with an exceptionally long half-life (57 hours, once-daily dosing); associated with a very high incidence of gastrointestinal ulceration and cutaneous reactions.

Selective COX-2 inhibitors (coxibs) were engineered to inhibit the inducible COX-2 enzyme at sites of inflammation while sparing the cytoprotective COX-1 enzyme in the gastrointestinal mucosa and platelets. The clinical prototype is Celecoxib; other agents include Etoricoxib and the injectable prodrug Parecoxib.

1. Clinical Benefits & Gastrointestinal Safety

• Analgesic & Anti-Inflammatory Efficacy: Display therapeutic potency identical to non-selective NSAIDs in osteoarthritis, rheumatoid arthritis, and acute pain.
• Reduced Gastropathy: By preserving gastric mucosal COX-1, coxibs reduce the incidence of endoscopically confirmed gastroduodenal ulcers, gastrointestinal perforations, and bleeding by approximately 50% compared to traditional NSAIDs.
• No Antiplatelet Action: At therapeutic doses, coxibs do not inhibit platelet COX-1 or reduce TXA₂ production, exerting no effect on bleeding time or primary hemostasis.

2. The Cardiovascular Thrombotic Paradox

3. Celecoxib Properties & Preferential COX-2 Inhibitors

• Celecoxib Pharmacokinetics: Readily absorbed (peak concentration in 3 hours); highly protein-bound; elimination half-life is ~11 hours (dosed once or twice daily). Extensively metabolized by hepatic CYP2C9; interacts with warfarin, requiring INR monitoring.
• Sulfonamide Cross-Allergy: Celecoxib contains a sulfonamide moiety in its chemical structure; can cause skin rashes and is contraindicated in patients with documented severe sulfonamide hypersensitivity.
• Preferential COX-2 Inhibitors:
  • Meloxicam: An oxicam derivative that preferentially inhibits COX-2 over COX-1, particularly at the low anti-arthritic dose of 7.5 mg/day. Demonstrates significantly lower gastrointestinal complications than piroxicam, diclofenac, or naproxen, and does not prolong in vivo bleeding time. Selectivity is lost at higher doses (15 mg/day).
  • Nimesulide: A sulfonanilide preferential COX-2 inhibitor; associated with severe, idiosyncratic hepatotoxicity (restricted or banned in multiple jurisdictions).
  • Nabumetone: A non-acidic prodrug converted in the liver to the active 6-MNA metabolite; preferentially inhibits COX-2, producing very low rates of gastric ulceration.

Paracetamol (Acetaminophen, APAP) is the active metabolite of phenacetin and the world’s most widely utilized over-the-counter analgesic and antipyretic. Unlike NSAIDs, paracetamol possesses negligible peripheral anti-inflammatory activity and does not impair platelet aggregation, damage the gastric mucosa, or disrupt renal blood flow.

1. Mechanism of Action

Paracetamol acts primarily within the central nervous system. It inhibits central cyclooxygenase activity (acting on the putative COX-3 / peroxidase catalytic site) to decrease hypothalamic PGE₂ synthesis, resetting the elevated thermoregulatory set-point to produce antipyresis and raising the central pain threshold. It is inactive at peripheral inflammatory sites because inflamed tissues contain high concentrations of lipid peroxides that override paracetamol’s inhibitory action on COX enzymes.

2. Clinical Advantages over Aspirin

• Does not damage the gastric mucosal barrier (drug of choice in peptic ulcer disease and gastritis).
• Does not inhibit platelet COX-1 or increase bleeding time (safe in hemophilia, thrombocytopenia, and preoperatively).
• Does not affect renal uric acid tubular excretion (safe in gout patients taking probenecid).
• Does not trigger bronchospasm in patients with aspirin-exacerbated respiratory disease (AERD).
• Does NOT cause Reye’s syndrome; the first-line antipyretic and analgesic for infants, children, and adolescents with viral infections.

3. Acute Paracetamol Poisoning & Hepatotoxicity

The following authoritative biomedical reference works and national guidelines were verified in the compilation of this study note:

• Goodman & Gilman’s: Brunton, L.L., Hilal-Dandan, R. and Knollmann, B.C. (2018) Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th edn. New York: McGraw-Hill Education. [Chapter 32: Histamine, Bradykinin, and Their Antagonists; Chapter 33: 5-Hydroxytryptamine (Serotonin) and Dopamine; Chapter 37: Prostaglandins and Eicosanoids; Chapter 38: Analgesic-Antipyretic and Anti-inflammatory Agents].
• Katzung’s Pharmacology: Katzung, B.G. and Vanderah, T.W. (2021) Basic & Clinical Pharmacology. 15th edn. New York: McGraw-Hill Education. [Chapter 16: Histamine, Serotonin, and the Ergot Alkaloids; Chapter 18: The Eicosanoids; Chapter 36: Nonsteroidal Anti-Inflammatory Drugs].
• Rang & Dale’s Pharmacology: Ritter, J.M., Flower, R., Henderson, G., Loke, Y.K., MacEwan, D. and Rang, H.P. (2020) Rang & Dale’s Pharmacology. 9th edn. Edinburgh: Elsevier. [Chapter 18: Chemical Mediators and the Cellular Mechanisms of Inflammation and Allergy; Chapter 27: Anti-inflammatory and Immunosuppressive Drugs].
• Lippincott Illustrated Reviews: Whalen, K. (2019) Lippincott Illustrated Reviews: Pharmacology. 7th edn. Philadelphia: Wolters Kluwer. [Chapter 42: Autacoids and Autacoid Antagonists; Chapter 44: Anti-inflammatory, Antipyretic, and Analgesic Agents].
• Uganda Clinical Guidelines: Ministry of Health Uganda (2023) Uganda Clinical Guidelines: National Guidelines for the Management of Common Conditions. Kampala: Ministry of Health. [Section 1.8: Management of Acute Poisoning and Anaphylaxis; Section 16: Postpartum Hemorrhage Management Protocols].